Phaseline

Companies › Harmony Biosciences Management

Harmony Biosciences Management: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 2, 1 Phase 1; Other, Neurology, Psychiatry; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pitolisant (HBS-301)
Histamine H3 receptor inverse agonist
HRH3Phase 3Prader-Willi Syndrome; Idiopathic Hypersomnia; EDS; Autism Spectrum DisorderApr 2027
HBS-104–Phase 1Sleep DeprivationFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05953389Pitolisant (HBS-301)Phase 2Autism Spectrum DisorderPsychiatryOct 2025
NCT07848659HBS-104Phase 1Sleep DeprivationOtherFeb 2027
NCT06366464Pitolisant (HBS-301)Phase 3Prader-Willi SyndromeOtherApr 2027
NCT07500090Pitolisant (HBS-301)Phase 3Idiopathic HypersomniaNeurologyOct 2027
NCT07675135Pitolisant (HBS-301)Phase 3EDSNeurologyOct 2027

Targets

HRH3 (1)

Companies with the same targets

Suven Life Sciences

Companies built like this

Novadip Biosciences Nanjing Minova Pharmaceutical Pharmazz Ensysce Biosciences Vigonvita Life Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.